A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1


About this study

The purpose of the study is to determine if the investigational medicine, lumasiran, is able to reduce the production of oxalate in the liver and to evaluate the safety of lumasiran and how the body responds to it.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Has confirmation of primary hyperoxaluria type 1 (PH1).
  • Meets urinary oxalate excretion requirements.
  • If taking Vitamin B6 (pyridoxine), must have been on stable regimen for at least 90 days. 

Exclusion Criteria:

  • Abnormal serum creatinine levels at screening for infants who are less than 1 year old.
  • Does not have relatively preserved kidney function.
  • Clinical evidence of systemic oxalosis.
  • History of kidney or liver transplant.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

David Sas, D.O.

Closed for enrollment

Contact information:

Barbara Seide CCRP

(507) 255-0387


More information


Publications are currently not available

Mayo Clinic Footer